Professor of Neurology, Brigham and Women's Hospital
Neurology
Dr. Patrick Y. Wen, MD
|
|
Give Review
Patrick Y. Wen, MD works in the field of Neurology. He graduated from Barts and The London School of Medicine and Dentistry. He received awards:"America's Top Doctors", "Boston Magazine" and "Super Doctor". Patrick Y. Wen is also published. He has 102 publications published. The lastest publication: "Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials clinical outcome assessment endpoints workshop (October 15, 2014, Bethesda MD).' He accepts Medicare payments and is listed with Medicare.gov.
Publications
- The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab.
- A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with Gliomas undergoing radiotherapy.
- A prognostic cytogenetic scoring System to guide the adjuvant management of patients with atypical meningioma.
- Neuro-oncology in 2015: Progress in glioma diagnosis, classification and treatment.
- Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model.
- CNS AntiCancer Drug Discovery and Development Conference White Paper.
- Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in ne...
- Immunotherapy response assessment in neuro-oncology: a report of the RANO working group.
- Expression profiles of 151 pediatric low-grade Gliomas reveal molecular differences associated with location and histological subtype.
- Central Nervous System Cancers, Version 1.2015.
- How treatment monitoring is influencing treatment decisions in glioblastomas.
- Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma.
- Glioma in 2014: unravelling tumour heterogeneity-implications for therapy.
- Combining progression-free survival and overall survival as a novel composite endpoint for glioblastoma trials.
- Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma.
- Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma.
- Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review.
- Vandetanib plus sirolimus in adults with recurrent glioblastoma: results of a phase I and dose expansion cohort study.
- Facing the future of Brain tumor clinical research.
- Phase 2 study of bosutinib, a Src inhibitor, in adults with recurrent glioblastoma.
- Central Nervous system cancers, version 2.2014.
- Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade Gliomas.
- Medical management of Brain tumors and the sequelae of treatment.
- Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD).
- Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage Gliomas.
- Combined VEGF and CXCR4 antagonism targets the GBM stem Cell population and synergistically improves survival in an intracranial mouse model of glioblastoma.
- Immunotherapy advances for glioblastoma.
- Brain Malignancy Steering Committee clinical trials planning workshop: Report from the Targeted Therapies Working Group.
- Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors.
- Retrospective study of using carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab.
- Adjuvant radiation therapy, local recurrence, and the need for salvage therapy in atypical meningioma.
- Leptomeningeal metastasis: a Response Assessment in Neuro-Oncology critical review of endpoints and response criteria of published randomized clinical trials.
- Spin-echo echo-planar perfusion prior to chemoradiation is a strong independent predictor of progression-free and overall survival in newly diagnosed glioblastoma.
- Histogram analysis of apparent diffusion coefficient within enhancing and nonenhancing tumor volumes in recurrent glioblastoma patients treated with bevacizumab.
- Targeted therapies: Further delineating bevacizumab's response spectrum.
- The role of targeted therapies in the management of progressive glioblastoma : A Systematic review and evidence-based clinical practice guideline.
- The role of cytotoxic chemotherapy in the management of progressive glioblastoma : A Systematic review and evidence-based clinical practice guideline.
- Tumor associated seizures in glioblastomas are influenced by survival gene expression in a region-specific manner: A gene expression imaging study.
- Controversies in neuro-oncology: does valganciclovir have a role in the treatment of high-grade Gliomas?
- Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review.
- Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02.
- Current status of antiangiogenic therapies for glioblastomas.
- Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation.
- Recurrent high-grade glioma treated with bevacizumab: prognostic value of MGMT methylation, EGFR status and pretreatment MRI in determining response and survival.
- Challenges relating to solid tumour Brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group.
- Challenges relating to solid tumour Brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group.
- The Role of MGMT Testing in Clinical Practice: A Report of the Association for Molecular Pathology.
- Biomarker-based adaptive trials for patients with glioblastoma--lessons from I-SPY 2.
- RTOG 0913: A Phase 1 Study of Daily Everolimus (RAD001) in Combination With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma.
- Vessel architectural imaging identifies Cancer patient responders to anti-angiogenic therapy.
- Recurrent glioblastoma: Volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevac...
- Retrospective analysis of the tolerability and activity of lacosamide in patients with Brain tumors: clinical article.
- Selective Enhancements in 2D Fourier Transform Optical Spectroscopy with Tailored Pulse Shapes.
- Enhancing radiation therapy for patients with glioblastoma.
- Treatment Options in Newly Diagnosed Glioblastoma.
- Phase 2 study of dose-intense temozolomide in recurrent glioblastoma.
- Challenges With Defining Response to Antitumor Agents in Pediatric Neuro-Oncology: A Report From the Response Assessment in Pediatric Neuro-Oncology (RAPNO) Working Gr...
- PCV for anaplastic oligodendroGliomas: back to the future or a step backwards? : A point/counterpoint discussion.
- A phase II trial of oral gimatecan for recurrent glioblastoma.
- A Phase I/II Trial of Pazopanib in Combination with Lapatinib in Adult Patients with Relapsed Malignant Glioma.
- Cytokines associated with Toxicity in the treatment of recurrent glioblastoma with aflibercept.
- Multicenter phase II study of rituximab and temozolomide in recurrent primary central Nervous system lymphoma.
- Prospective, high-throughput molecular profiling of human Gliomas.
- Current clinical development of PI3K pathway inhibitors in glioblastoma.
- DNA Fragmentation Simulation Method (FSM) and Fragment Size Matching Improve aCGH Performance of FFPE Tissues.
- Central Nervous System Complications of Cancer Therapy.
- Neurologic complications of Cancer drug therapies.
- Response to C. Massard et al.
- Outcomes after discontinuation of antiepileptic drugs after surgery in patients with low grade Brain tumors and meningiomas.
- Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2.
- Increased Survival of Glioblastoma Patients who Respond to Anti-angiogenic Therapy with Elevated Blood Perfusion.
- Targeting DNA repair and the Cell cycle in glioblastoma.
- Ridaforolimus for patients with progressive or recurrent malignant glioma: a perisurgical, sequential, ascending-dose trial.
- Epidemiology of Brain Metastases.
- Discontinuing Bevacizumab in Patients with Glioblastoma: An Ethical Analysis.
- Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma.
- An LXR agonist promotes GBM Cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway.
- Valproic acid as the AED of choice for patients with glioblastoma?: The jury is out.
- It Is Time to Include Patients With Brain Tumors in Phase I Trials in Oncology.
- Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery.
- Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients.
- Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab.
- Myeloid Biomarkers Associated with Glioblastoma Response to Anti-Vascular Endothelial Growth Factor Therapy with Aflibercept.
- International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors.
- Phase II Study of Aflibercept in Recurrent Malignant Glioma: A North American Brain Tumor Consortium Study.
- Application of Novel Response/Progression Measures for Surgically Delivered Therapies for Gliomas.
- A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03.
- Central Nervous system cancers.
- A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma.
- Clinical trial end points for high-grade glioma: the evolving landscape.
- Signal transduction inhibitors and antiangiogenic therapies for malignant glioma.
- Survival among patients with primary central Nervous system lymphoma, 1973-2004.
- Response assessment in neuro-oncology.
- Lonafarnib (SCH66336) improves the activity of temozolomide and radiation for orthotopic malignant Gliomas.
- Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" reVascularization as mode of escape.
- Crude drugs as antiCancer agents.
- Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab.
- Longitudinal MRI evidence for decreased survival among periventricular glioblastoma.
- Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard...
- Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma.
- Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials clinical outcome assessment endpoints workshop (October 15, 2014, Bethesda MD).
Schools
University Of London Faculty Of Med
North Middlesex Hospital London
St Bartholomew39s London Uk
Harvard Longwood Neurology Prg
London Chest Hospital London
Nat39l Hospital Nervous Diseasesuk
Whittington Hospital London
Procedures Preformed
- EEG (Electroencephalogram)
Conditions Treated
- Alzheimer's Disease
- Ataxia
- Bell's Palsy
- Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
- View All
Doctors Specialties
- Neurology
Accepted Insurances
Awards
- America's Top Doctors
- Boston Magazine
- Super Doctor
Education
-
Brigham and Women's Hospital -
Barts and The London School of Medicine and Dentistry
Hospital
-
Dana-Farber Cancer Institute -
Brigham and Women's Hospital
Drug Facts
| NPI NUMBER | 1053393496 | |
| NPPES Provider LastName | WEN | |
| NPPES Provider FirstName | PATRICK | |
| NPPES Provider ZIPCode | 021156110 | |
| NPPES Provider State | MA | |
| Specialty Description | Neurology | |
| Total Claim Count | 185.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1053393496 |
| Last Name Of The Provider | WEN |
| First Name Of The Provider | PATRICK |
| View All |
Similar Doctors
|
|
Dr. Costas Michaelides, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Zeina N. El-Chemali, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alexander Rotenberg, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jose R. Romero, MD
This Doctor is OpenDoctor Recommended.
|